A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Clinical Trial ID NCT01246960

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.	Ann Oncol	2016	1.53
2	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
3	Treatment options in patients with metastatic gastric cancer: current status and future perspectives.	World J Gastroenterol	2014	1.02
4	Clinical management of advanced gastric cancer: the role of new molecular drugs.	World J Gastroenterol	2014	0.92
5	The progress of targeted therapy in advanced gastric cancer.	Biomark Res	2013	0.89
6	Advances in targeted therapies and new promising targets in esophageal cancer.	Oncotarget	2015	0.87
7	Targeted therapy in gastroesophageal cancers: past, present and future.	Gastroenterol Rep (Oxf)	2015	0.85
8	Clinical utility of ramucirumab in advanced gastric cancer.	Biologics	2015	0.79
9	Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.	BMC Cancer	2016	0.75